Safer Joshua D, Crawford Tara M, Holick Michael F
Section of Endocrinology, Diabetes, and Nutrition, Boston University School of Medicine, 715 Albany Street, Room M-1022, Boston, Massachusetts 02118, USA.
Endocrinology. 2004 May;145(5):2357-61. doi: 10.1210/en.2003-1696. Epub 2004 Jan 21.
The importance of thyroid hormone (TH) in wound healing is not well understood. To gain insight, we evaluated the impact of TH deficiency on wound-healing genes in cultured keratinocytes. By RT-PCR, keratin 6a (K6a) and 16 (K16) gene expression in TH replete cells was 3.8- (P < 0.005) and 1.9-fold (P < 0.05) greater, respectively, than expression in TH-deficient cells. By real-time PCR, TH replete cell expression of K6a, K16, and K17 was greater than in deficient cells: 18- (P < 0.001), 10- (P < 0.001), and 4-fold (P < 0.005), respectively. To examine TH requirement for optimal wound healing, we contrasted TH-deficient vs. ip T(3)-treated mice. Four days after wounding, ip T(3)-treated mice had twice the degree of wound closure as hypothyroid mice (P < 0.001). By RT-PCR, K6a and K17 gene expression from control mouse skin was greater than from hypothyroid mouse skin: 5- (P < 0.001) and 1.7-fold (P < 0.05), respectively. T(3) is necessary for the keratinocyte proliferation required for optimal wound healing. T(3) exerts influence by stimulating expression of the wound-healing keratin genes. Thus, for hypothyroid patients undergoing surgery that cannot be delayed until euthyroidism is achieved, our data support T(3) treatment for the perioperative period.
甲状腺激素（TH）在伤口愈合中的重要性尚未得到充分理解。为了深入了解，我们评估了TH缺乏对培养的角质形成细胞中伤口愈合相关基因的影响。通过逆转录聚合酶链反应（RT-PCR），甲状腺功能正常的细胞中角蛋白6a（K6a）和16（K16）基因的表达分别比甲状腺功能缺乏的细胞高3.8倍（P < 0.005）和1.9倍（P < 0.05）。通过实时定量PCR，甲状腺功能正常的细胞中K6a、K16和K17的表达高于缺乏甲状腺激素的细胞：分别为18倍（P < 0.001）、10倍（P < 0.001）和4倍（P < 0.005）。为了研究最佳伤口愈合对TH的需求，我们对比了甲状腺功能缺乏与腹腔注射三碘甲状腺原氨酸（T3）治疗的小鼠。受伤4天后，腹腔注射T3治疗的小鼠伤口闭合程度是甲状腺功能减退小鼠的两倍（P < 0.001）。通过RT-PCR，对照小鼠皮肤中K6a和K17基因的表达高于甲状腺功能减退小鼠的皮肤：分别为5倍（P < 0.001）和1.7倍（P < 0.05）。T3是最佳伤口愈合所需的角质形成细胞增殖所必需的。T3通过刺激伤口愈合角蛋白基因的表达发挥作用。因此，对于无法推迟到甲状腺功能正常后再进行手术的甲状腺功能减退患者，我们的数据支持在围手术期进行T3治疗。
